MDWDNasdaq

MediWound Ltd.

Healthcare·Metabolic·Commercial·Yavne, Israel
Metabolic

MediWound Ltd. (MDWD): 2 pipeline candidates · 1 upcoming catalyst · 3 clinical trials. Updated within the last hour.

7.0/10

BioSniper Score

5-factor signal · derived from public data

Cash RunwayN/A

N/A

Financial Health8.5

D/E 0.98 · 0% dilution

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth4.6

2 candidates

Catalyst Momentum2.0

1 upcoming, next in ~256d

Insider Signal10.0

6 buys · 0 sells (180d)

A transparent, data-derived signal for MediWound Ltd.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$182.5M

Cash

$4.8M

Quarterly Burn

Runway

Revenue

Cash Runway vs Catalysts

Upcoming catalyst timeline.

Today~9 mo out
Catalyst within runway

Pipeline (2 candidates)

Upcoming Catalysts (1)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

71

Total value held

$52.3M

HolderSharesValue
investor ab872,093$14.0M
blackrock, inc.445,834$7.2M
meitav investment house ltd371,868$6.0M
sphera funds management ltd.273,192$4.4M
state street corp143,770$2.3M
ark investment management llc129,961$2.1M
geode capital management, llc121,958$2.0M
northern trust corp121,776$2.0M
dafna capital management llc94,405$1.5M
morgan stanley88,473$1.4M

Showing top 10 of 71 institutional holders of MediWound Ltd.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

3 clinical trials·1 FDA decision·CEO: Mr. Ofer Gonen B.Sc.

Frequently asked questions

How many drug candidates are in MediWound Ltd.'s pipeline?

MediWound Ltd. (MDWD) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is MediWound Ltd.'s lead drug candidate?

MediWound Ltd.'s most advanced tracked candidate is escharex (Phase 3) for Venous Leg Ulcer (VLU).

What is MediWound Ltd.'s next catalyst?

MediWound Ltd.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Multicenter, Prospective, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study Perf" — expected March 1, 2027.

What is MediWound Ltd.'s market capitalization?

MediWound Ltd.'s market capitalization is approximately $182.5M.

Who is the CEO of MediWound Ltd.?

Mr. Ofer Gonen B.Sc. is the chief executive officer of MediWound Ltd. (MDWD).

Get the full picture on MediWound Ltd.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.